Work

Clinical remission in patients with severe eosinophilic asthma treated with benralizumab who were randomised to reduce their inhaled corticosteroid/formoterol dose: SHAMAL post-hoc analysis

Year: 2024

Type: conference-abstract

DOI: 10.1183/13993003.congress-2024.pa1194

Authors: Gilles Devouassoux, David J Jackson, Frank F Käßner, Cristiano Caruso, Anat Shavit, Lynda Olinger, Andrew Menzies-Gow

Institutions: Lyon 1 Université, Inserm, Hôpital de la Croix-Rousse, Virologie et Pathologies Humaines, Guy's Hospital, King's College London, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, AstraZeneca (United Kingdom)

Language: English

Topic: Asthma and respiratory diseases

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4404101270

Cites:

Cited by: 2

Related to: 10